Sanofi’s Board of Directors has proposed the appointment of two directors, Christian Brandts and Barbara Lavernos, as well as the ratification of appointment by cooptation of Gilles Schnepp and the renewal of the mandates of Fabienne Lecorvaisier and Melanie Lee.
Christian Brandts is currently Director at the University Cancer Center Frankfurt. In addition to his duties, Brandts is pursuing research activities focused on translational cancer research and personalised oncology. He is part of national and international networks of oncology experts and a member of the board of the Organisation of European Cancer Institutes (OECI).
Brandts is a graduate from the Medical School of the Free University of Berlin, and he specialised in Internal Medicine and Hematology / Oncology at the Charité University Hospital in Berlin and the University Hospital in Münster.
Barbara Lavernos took over in February 2021 as President, Research, Innovation and Technologies of the L'Oréal Group, having spent her career at l'Oréal, which she joined in 1991. In 2014, she was appointed COO and member of the Group’s Executive Committee, and she has led from the end of 2018 all the IT teams with the group’s technological transformation as her mission.
Barbara Lavernos graduated from Ecole des Hautes Etudes d’Ingénieur en génie chimique (School of Advanced Studies in Chemical Engineering - HEI).
“The arrivals of Christian Brandts and Barbara Lavernos will strengthen the board of directors’ expertise in technology and science, notably in the field of oncology. The board of directors thus continues to diversify its profiles and competencies, in line with its roadmap,” said Serge Weinberg, Chairman of the board of directors.
The composition of the board’s specialised committees will be reviewed following the annual general meeting of shareholders scheduled for April 30, 2021.
